Meeting
2020 ASCO Virtual Scientific Program
Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC.
Authors
Sally CM Lau
Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
Sally CM Lau , Stephanie WY Wong , Ben X Wang , Devalben Patel , Aline Fusco Fares , Ming-Sound Tsao , Penelope Ann Bradbury , Geoffrey Liu , Natasha B. Leighl , Frances A. Shepherd , Pamela S Ohashi , Adrian G. Sacher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immunobiology
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3084)
DOI
10.1200/JCO.2020.38.15_suppl.3084
Abstract #
3084
Poster Bd #
148
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models.
First Author: Roberto Ferrara
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Immune checkpoint inhibitor responses in KIT-mutated metastatic melanoma.
First Author: Meredith Ann McKean
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2019 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
First Author: Andreas Nicholas Saltos